$RVPH

REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights - U.S. composition of matter patent application filed seeking accelerated review for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046

Nasdaq, Inc. said it will delist multiple securities that have been suspended and not traded on Nasdaq since late 2025 through July 2026, including common stock and warrants of CERo Therapeutics Holdings, Captivision Inc., Actelis Networks, American Rebel Holdings, Reviva Pharmaceuticals, Bitcoin Depot, Inotiv, GoHealth, Functional Brands, Sleep Number, and others. The announcement cites Nasdaq delisting rules.

Reviva (RVPH) reported a reduced net loss of $3.2 million in Q1 2026, alongside an increase in cash to $22.2 million after a $10.0 million equity offering. The company filed a provisional patent for a new form of brilaroxazine, potentially extending its exclusivity until 2046, and anticipates FDA feedback and the start of RECOVER-2 Phase 3 trial enrollment in mid-2026 and Q3 2026, respectively. Reviva's common stock will transition from Nasdaq to the OTCQB Venture Market on May 14, 2026.

Reviva Pharmaceuticals announced that its Founder, President, and CEO, Laxminarayan Bhat, PhD, will participate in a fireside chat hosted by A.G.P. Equity Research Analyst James Molloy on April 27, 2026. The discussion will focus on recent developments and upcoming milestones for brilaroxazine, a clinical-stage drug candidate with potential across multiple neuropsychiatric and inflammatory indications. Brilaroxazine recently showed positive Phase 3 results for schizophrenia and has received Orphan Drug Designation for PAH and IPF.

Reviva Pharmaceuticals Holdings, Inc. announced that its Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will present at the Sachs 9th Annual Neuroscience Innovation Forum on January 11, 2026. The presentation will cover the company's work in developing therapies for central nervous system, inflammatory, and cardiometabolic diseases. Reviva is a late-stage biopharmaceutical company with two in-house discovered drug candidates, brilaroxazine and RP1208, in its pipeline.

CUPERTINO, Calif., Oct. 07, 2025 ( GLOBE NEWSWIRE ) -- Reviva Pharmaceuticals Holdings, Inc. ( NASDAQ:RVPH ) ( "Reviva" or the "Company" ) , a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system ( CNS ) , ...

CUPERTINO, Calif., Oct. 07, 2025 ( GLOBE NEWSWIRE ) -- Reviva Pharmaceuticals Holdings, Inc. ( NASDAQ: RVPH ) ( "Reviva" or the "Company" ) , a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system ( CNS ) , ...

CUPERTINO, Calif., Sept. 18, 2025 ( GLOBE NEWSWIRE ) -- Reviva Pharmaceuticals Holdings, Inc. ( NASDAQ: RVPH ) ( "Reviva" or the "Company" ) , a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system ( CNS ) , ...

CUPERTINO, Calif., Sept. 18, 2025 ( GLOBE NEWSWIRE ) -- Reviva Pharmaceuticals Holdings, Inc. ( NASDAQ: RVPH ) ( "Reviva" or the "Company" ) , a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system ( CNS ) , ...

Doctors have been diagnosing schizophrenia for more than a hundred years, but when it comes to treating this serious brain illness, the remedies still fall short.